AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar Prof3215 (< 20) Submitted: 9/15/2011 6:04:26 PM : Outperform Start Price: $1.25 AVII Score: -51.43

It's very low right now, but AVII has a proven technology used by the Department of Defense to quickly manufacture vaccines in two weeks in case of a bio-threat.

Featured Broker Partners


Advertisement